Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)
Close on Nov 17, 2026Market cap $253.10MP/E –Yield –
Enanta Pharmaceuticals price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Enanta Pharmaceuticals's price to book ratio was 3.3× on Nov 11, 2026, against 4.7× a year earlier. Over the last 5 years it ranged from 0.8× to 5.2×, with a median of 2.7×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.3× | −1.9 |
| 2025 | Dec 31, 2025 | 5.2× | +4.3 |
| 2024 | Dec 31, 2024 | 1.0× | +0.0 |
| 2023 | Dec 29, 2023 | 0.9× | −2.1 |
| 2022 | Dec 30, 2022 | 3.0× | −0.8 |
| 2021 | Dec 31, 2021 | 3.8× | +1.9 |
| 2020 | Dec 31, 2020 | 1.9× | −0.8 |
| 2019 | Dec 31, 2019 | 2.6× | −0.9 |
| 2018 | Dec 31, 2018 | 3.5× | −0.2 |
| 2017 | Dec 29, 2017 | 3.7× | +1.4 |
| 2016 | Dec 30, 2016 | 2.4× | −0.3 |
| 2015 | Dec 31, 2015 | 2.6× | −3.7 |
| 2014 | Dec 31, 2014 | 6.4× | +1.9 |
| 2013 | Dec 31, 2013 | 4.4× | – |
See a number that looks wrong?